The US regulator has cleared Cara Therapeutics' Korsuva (difelikefalin) as an injectable treatment for chronic itching, also known as pruritus, in these patients after a priority review.

The drug – which is injected three times weekly – was approved in the US last year as Korsuva, and is due to be launched there this month. It acts as an opioid agonist, targeting the kappa ...

As part of the deal, Cara (NASDAQ:CARA) will sell certain assets, liabilities, and rights for its lead candidate, ...